Healthcare Reimbursement And Service Utilization For One Year Of Post-Allogeneic Hematopoietic Cell Transplantation (Allohct) Care For Medicare Beneficiaries Ages 65 And Older With Acute Myeloid Leukemia

Objective: Acute myeloid leukemia (AML) is the most common indication for alloHCT in the United States (US) for Medicare beneficiaries. An increasing number of older patients are now able to undergo alloHCT; however, there is a significant gap in knowledge about their healthcare costs. The primary objective of this study was to assess healthcare reimbursement, service utilization, and overall survival for designated time points up to 1-year post-alloHCT for Medicare beneficiaries ages 65 and older in the US with an AML diagnosis.